Pharsight

Natroba generic

Natroba is a medicinal drug owned by Parapro Llc. Its active ingredient is spinosad. This drug was authorized for market use on January 18, 2011. Natroba has a total of 2 patents, one of which has already expired.

When will Natroba generic be available?

The generic version of Natroba is expected to be released after November 25, 2033. This date corresponds to the expiry of the last-standing patent of the drug: US9895388, about 'Methods and compositions useful for controlling cutaneous mites'. The expired patent, US6063771, pertained to 'Formulations for controlling human lice', which expired on July 25, 2023.

Natroba uses

Natroba, with its active ingredient spinosad, is used topically for the treatment of human scabies mite infestations and head lice. It effectively eradicates these pests by melting and delivering spinosad to the outermost layer of skin where these parasites breed and live. This drug is indicated for patients six months of age and older.

Natroba patent expiration

Natroba, owned by Parapro LLC, holds 2 patents, 1 of which has expired. The active patent: 'Methods and compositions useful for controlling cutaneous mites' (US9895388), will expire on November 25, 2033. After this date, the production of Natroba generics may commence. The expired patent, (US6063771), involved 'Formulations for controlling human lice'. Below are the details of the patent:

Natroba dosage

Want to ask something?